Poxel S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a POXEL.PA research report →
About the company
Poxel S. A. is a clinical-stage biopharmaceutical firm dedicated to discovering innovative therapies for a range of conditions, including metabolic disorders, type 2 diabetes, and liver ailments.
- CEO
- Nicolas Trouche
- IPO
- 2015
- Employees
- 6
- HQ
- Lyon, FR
Price Chart
- Market Cap
- $10.99M
- P/E
- -0.79
- P/S
- 1.44
- P/B
- -0.17
- EV/EBITDA
- -22.78
- Div Yield
- 0.00%
- Gross Margin
- 51.56%
- Op Margin
- -30.30%
- Net Margin
- -178.45%
- ROE
- 22.71%
- ROIC
- 557.05%
- Revenue
- $6.64M · 234.98%
- Net Income
- $-18,305,000 · 47.83%
- EPS
- $-0.38 · 58.24%
- Op Income
- $-3,662,000
- FCF YoY
- -100.00%
- 52W High
- $0.71
- 52W Low
- $0.19
- 50D MA
- $0.24
- 200D MA
- $0.27
- Beta
- 1.28
- Avg Volume
- 422.66K
Get TickerSpark's AI analysis on POXEL.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our POXEL.PA coverage
Recent articles, reports, and earnings notes.
No research on POXEL.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate POXEL.PA report →Similar companies
Peers in the same neighborhood.